Fresh analysis reveals that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional diet and exercise plans.
Research printed in a major health publication demonstrates that while obese individuals frequently drop about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"People using such drugs should be aware of the risk of quick rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
This pace of regain suggests a reversion to pre-treatment weight in about one and a half years.
Comparing Approaches
The study, which looked at 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
Scientists point out that people who lose weight through dieting usually have a more gradual weight regain—around 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Nutrition scientists believe the mechanism of the jabs accounts for the accelerated weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means appetite is unsuppressed, making binge eating much more probable."
An Ongoing Disease?
Health authorities recommend the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals argue that, given the high risk of weight regain, the treatment is often ongoing.
This view is echoed by pharmaceutical companies, who state that the findings "underscore the long-term character of obesity," similar to managing diseases like high blood pressure.
User Experiences
Users who have stopped the medication explain a intense resurgence of cravings.
"It felt as if something flipping and you become extremely hungry," described one woman.
This difficulty is compounded if individuals have not developed lasting lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, clinicians caution that while these medications are powerful agents for weight loss, they are not a standalone fix and lasting health benefits hinges on combined behavioural support.
